CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th.

Q4 2024 Earnings Call Transcript February 27, 2025 Ligand Pharmaceuticals Incorporated misses on earnings expectations.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational results posting revenues of $167 million, a 27% rise over prior year levels.

Robust financial performance driven by full year 2024 royalty revenue growth of 28%Reiterating 2025 financial guidance of $180-$200 million in ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Ligand Pharma (LGND – Research Report), with a price target ...

Arizona State Retirement System increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free ...

JUPITER, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo ...

(RTTNews) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal 2025 forecast.

JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $31.1 million in its fourth quarter. On a per-share basis, the Jupiter, Florida ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors ...

Researchers from the University of Barcelona and collaborators reported the discovery and preclinical characterization of novel imidazoline I2 receptor ligands (I2-IRs). Among the series, the most ...